BioSpace News Archive

PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina ® Focus Panel, AmpliSeq™ for Illumina ® Myeloid Panel and the TruSight™ Hereditary Cancer

140,000-square-foot facility will create more than 200 highly specialized manufacturing jobs to support KBI’s commercialization pipeline

Meso Scale Diagnostics, LLC. (MSD) today announced the commercial release of its V-PLEX® Serology Panels for COVID-19.

Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

Healthcare design innovation firm known for its ‘hospital in a box’ solution expands modular offerings with new MedModLabs initiative, first rolling out in Philadelphia to help address Pennsylvania’s poor testing rates

Novartis today announced that the US Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids

– Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation – – Xolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine’s 17 years of patient experience since its initial approval for allergic asthma –

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613 ® (devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Sara’s Cure and Sarcoma Alliance for Research through Collaboration (SARC) , Rafael will begin enrolling patient

GSK donates on behalf of consumers to make sure healthcare workers have the supplies they need as the COVID-19 pandemic continues